Protalix BioTherapeuticsPLX
Recorded

Protalix BioTherapeutics 2026 Stifel Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration28 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Colleen KusyAnalyst

All right. Good afternoon. Thanks for being here for the Stifel Healthcare Conference. My name is Colleen Kusy. I am one of the senior analysts here at Stifel, and I am pleased to have with us the Protalix team, including Dror Bashan, CEO, and Gilad Mamlok, CFO. We will have a formal presentation and then have some Q&A at the end.

Dror BashanPresident and CEO

Thank you, and thank you everybody for coming. I will start with a, I would say, a snapshot about the company. Protalix actually develop and manufacture and sell drugs, and we actually do it from concept to the market. We have two drugs approved. One is Elelyso, which is an ERT for Gaucher disease, for patients diagnosed with Gaucher, and the other one is Elfabrio, which is approved in 2023 for patients diagnosed with Fabry disease. Elelyso was licensed to Pfizer, except Brazil. In Brazil, we have our own operations. Chiesi, which is a private Italian company, we will discuss it a bit later, is the global licensor for Elfabrio. Elfabrio was approved originally in May of 2023, with a regimen of once in two weeks, both in the E.U. and the U.S.

Dror BashanPresident and CEO

About seven, eight months ago, at the beginning of March of this year, we got the once in four weeks approval in the E.U., which is a very nice achievement for us. Actually, 70% of the Fabry patients are outside the U.S., so this is very much important. They do well. In the last three years, the launch is a success, and they do well, and we will discuss it a bit later. This is, if I may say, is the business segment of Protalix, where we enjoy royalties from our partners and the milestone from time to time. The next one is a potential big upside. We have a program under phase II, advanced phase II, if I may say, for uncontrolled gout. We plan to finalize enrollment by Q1 next year, and actually a year from today to have the readout.

Dror BashanPresident and CEO

We speak about a pretty robust study with a high biostatistical power. We think that once we will open the code and have the readout, we will have very few questions left. These studies following a successful phase I with subject with hyperuricemia, so we know the mechanism of action works well. We have the reasons to believe that we have a fair chance to hit the endpoints in one or more of the four active arms. In addition, the last two, three years, we started to explore and get up the learning curve, and so we have already a couple of programs within selected rare renal disease indications. We are working on that, and I believe that within two years, we will have an interesting basket of rare renal early-stage program, let us say, between discovery to phase I. Just a minute. Protalix was based or was established, if I may say, both the unique technology where we can express complex human protein through plants as in suspension.

Dror BashanPresident and CEO

This is where Elelyso, Elfabrio, and the gout programs are expressed through. We have our own drug substance line in our site. We are competitive. It's unique platform, and we are pleased with that. For the future portfolio and pipeline, I assume we'll have a combination of program based on our platform and collaborations or licenses from third parties. It's per the indication, the unmet needs per indication. This is the pipeline portfolio, how it looks in a more graphic way. I would like to refer to our financial situation. Actually, today is, there are very few moments in my job at least, a year that you have professional joy, if I may say. Today, we published results. The market is pleased, so it's nice.

Dror BashanPresident and CEO

We just published the third quarter results, and we have achieved the accumulated $75.6 million. Already, we plan to meet the guidance or even exceed the guidance. It depends upon release of final release of batches. We sit on $48.5 million cash in deposits. Overall, we are in a position where we can plan and finance our strategy and our plans for the next few years. We have the means to finance, of course, the phase II in gout and the other operational responsibilities. Overall, it's a much more solid position that we have been earlier. So we are pleased with these results. We expect a good overall 2026. As we see the data that we get from Chiesi, we think the trend will continue for the foreseeable future.

Dror BashanPresident and CEO

We think, as I mentioned earlier about what I call the business segment or the royalties and milestone from Chiesi and Elelyso, this will grow and will increase our profitability in time. I would like to spend some time about the gout program. It's very much important. It's a significant upside for our business model. We are now running the RELEASE study. We are more or less two-thirds enrolled. We expect to finalize enrollment by Q1, as I mentioned earlier. Here is one slide, a bit about the disease. What is gout? About elevated plasma uric acid, which actually create crystals in the joint and damages them. There are, I would say, about 11 million gout patients in the U.S. Most of them are lighter patients, if I may say. We are targeting the more severe part, which is called uncontrolled gout.

Dror BashanPresident and CEO

I will show a little bit later the estimated numbers we are talking about. When you reach a situation where you are in uncontrolled gout, it's usually a very low quality of life. It's a pretty severe condition. The idea is actually to reduce, if I may say, in a quick or rapid way, the uric acid level in the plasma. This is what PRX-115 is about. About the numbers I mentioned, the 11 million overall gout patients, there are about eligible or uncontrolled gout patients, the severe stage of about 150,000-200,000 patients. This is why we put around 180,000. Right now, bless you. Right now, one therapy is approved on the label for uncontrolled gout patients. It's Krystexxa by Amgen. We don't know the exact number. I mean, they grow. It's about a $1.5 billion-$1.6 billion drug probably this year.

Dror BashanPresident and CEO

We assume it's, I assume, maybe a bit more, 10,000-12,000. We just don't know exactly. They don't publish number of patients. Overall, we think that by the time we will, if indeed the company mature, the program matures positively, so by 2031, this market will be a couple of billions of dollars of market from a value point of view. If indeed we win the end points of this phase II that is going on, we will have potentially, of course, but a differentiated profile therapy to compete well on the market and address the unmet needs of the patients. I think it's extremely significant, both for patients and from a business point of view. So, what we aim to do is actually to reduce the burden of the infusion. We are testing once in four, once in six, and once in eight weeks infusion.

Dror BashanPresident and CEO

Krystexxa today is approved for once in two weeks. We also have one arm, active arm, with once in four weeks without methotrexate, which is also, if we meet the end point, it could be very much significant for the patients. Clearly, we aim to have, due to the change in the enzyme that we did when we actually designed this molecule, so we did the change at C250, and we have designed a special PEG, which is a small PEG, 3.4 kilodalton. It's bifunctional. We think that we have potentially, of course, a favorable masking profile, and therefore, we will be able not only to, let's say, reduce the frequency of the infusion, but hopefully to have a good immunogenicity and safety profile for this product. Together, it could be a home run for us and a good alternative for the patients or for discussion with the treating physicians.

Dror BashanPresident and CEO

So when we conducted the phase I, it was done with 64 subjects with hyperuricemia. We had eight cohorts. It was a single ascending dose. We started with one or two milligram and went up to 36 milligram at the eighth cohort. Overall, we had eight subject per each cohort, six on the active, if I may say, enzyme, and two on placebo. You can see here the results from the phase I. We put together the upper, if I may say, three cohorts. By the way, we chose the higher one, the 36 milligram, and this is the one that we test now at phase II. You can see actually that the 36 milligram, we see that in all subject, we are way below the six milligram per deciliter. This is the well-known biomarker for gout, to test the gout patients.

Dror BashanPresident and CEO

We see that four out of the six subject in this cohort were below two milligram per deciliter, which is a significant, if I may say, input. We looked at the different cohort. We saw as we went up the ladder of the strength, we got better and better results, including safety issues or safety events. This is after careful consideration, we looked into it and chose this one to continue with. So overall, it's a generally well tolerated. We had one anaphylactic event in the second cohort after five minutes of the infusion. It was not related to our enzyme. It was carefully checked. The patient is okay. This is it. Knock on wood. This study, it's silent so far, in this respect at least. We can see different inputs related, I would say, safety issues.

Dror BashanPresident and CEO

We will see in phase II, the phase I is a single ascending dose. In phase II, where we have the multiple dose, we will see the profile from an immunogenicity and safety point of view. It will be we can conclude much better within the year where we are with the result. After we analyzed the data, we went into phase II, it was discussed with the FDA. We have five arms. One is a placebo and four active arms. As I mentioned earlier, once in four, once in six, and once in eight weeks with methotrexate, and once in four weeks without methotrexate. Two-thirds in. We have two major events. One is to finalize enrollment within the next four or five months, and the second one is the readout within a year, as enrollment, if indeed it flies. This is the plan. You can see here the comparison of the different arms, and clearly, once in four, once in six, or once in eight weeks is a significant, I would say, improvement for patients, of course, as long, I'm sorry, the immunogenicity and safety profile are good.

Dror BashanPresident and CEO

Clearly, if the once in four weeks we fly without the immunomodulator, this is also a nice proposition for patients. A bit about Chiesi. Chiesi is a private health company. Originally, it's based in Italy. They have three different businesses. One of them is the rare disease business, where we are part of. We have a high priority, a top priority attention. It's one of their biggest products. It grows. They do very well on the market.

Dror BashanPresident and CEO

The once in four weeks approved in March clearly enhances it, and we see, I would say, years ahead of continued growth, which is very important for us as a small company, which enable us to execute on the rest of the programs and plans. As for Elelyso, in Brazil, we do well. We have about 25% market share against Cerezyme, which is the main enzyme. Pfizer does to a less extent, if I may say. They are focused on other programs, if I may say. Overall, we sell from Elelyso $22 million-$25 million. This is the range, depends on different treatments. It's steady. In Brazil, we grow slowly, but this is give or take. Fabry will be totally different. At Fabry, we expect, from whatever we understand and speak to Chiesi and analyze the market, to reach 15%-25%, or 15%-20%. This was within. We think it will be even higher.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day